Emerging trend of cross-border mergers and acquisitions in pharmaceutical industry – Sohu Finance-dataload

The trend of cross-border mergers and acquisitions in pharmaceutical industry is emerging – Sohu financial, pharmaceutical, biotechnology field mergers and acquisitions in recent years surging. Pfizer’s $160 billion acquisition of AI Erjian, has become the largest in the history of the pharmaceutical industry mergers and acquisitions; domestic green medical group acquired Healthe Care, also set a record amount of Chinese pharmaceutical companies overseas mergers and acquisitions. Present situation of biological medicine has become highly concentrated in petroleum and natural gas and retail industry, Chinese foreign investment merger related stock movements of one of the three most active industries. Public information of the Ministry of Commerce shows that in 2014, China’s total foreign investment amounted to about 140 billion US dollars, of which, bio medicine accounted for about 12% of the total market share. According to the Chinese International Trade Promotion Committee published information, from 2009 to 2013, the total foreign direct investment Chinese enterprises the average annual growth rate of 17.5%, and more than $100 billion for the first time in 2013. From the amount and amount of transactions in Shanghai’s local enterprises, health care and services account for about 5-10% of the share. At present, the global biopharmaceutical market is highly concentrated. L.E.K (Ai Yikai) advisory report said that by 2016, North America, the major EU countries, as well as Japan and South Korea’s pharmaceutical market expenditure, nearly 60% of the global total expenditure. But the market of developing countries is growing faster, BRIC five year market compound annual growth rate (2016) more than 10%, while the U.S. compound annual growth rate of around 3%, the EU countries (Germany, France, Italy, Britain, West) the average annual compound growth rate of about 1%. L.E.K (Ai Yikai) consulting believes that the American medical market as the focus of investment: a lower threshold of non prescription drugs, health food, medical equipment and various types of equipment, and related research and laboratory and imaging equipment. In the United States and other developed markets, biopharmaceutical companies will continue to focus on wearable diagnostic devices, orphan drugs and biological analogues. Medical technology is the focus of most private Holdings Company in the field of medical investment. India market investment focus mainly include: hospital and specialist care service center, diagnosis and pathology laboratory, bio pharmaceutical manufacturing, research and production of customized service. Specifically, the pharmaceutical industry in India, especially generics, is still the most popular market. And the medical service providers in India, such as medical logistics, have been developing rapidly in recent years, and are also sought after by investors. Three factors help mergers and acquisitions, mergers and acquisitions is the best choice to enhance the concentration of China’s pharmaceutical industry and make it bigger and stronger. According to statistics, the number of pharmaceutical companies in China is 4516, five times the number of pharmaceutical companies in the United States, while the size of China’s pharmaceutical market is only 13 of the United States market. Chinese pharmaceutical companies have 3 kinds and 6 kinds of approvals for generic drugs. This fully shows that China’s pharmaceutical enterprises low level homogenization competition is obvious. It is urgent for Chinese pharmaceutical enterprises to increase their industry concentration to reduce and avoid low-level homogenization competition. There is no doubt that the merger and acquisition of pharmaceutical enterprises is the most direct and convenient way to reduce the competition of homogeneous Enterprises

医药行业跨境并购趋势显现-搜狐财经   制药、生物科技领域近年来并购风起云涌。辉瑞以1600亿美元收购艾尔建,成为至今医药界史上最大的并购案;国内绿叶医疗集团收购Healthe Care,也刷新了中国药企海外并购金额的纪录。  呈现高度集中态势  生物医药已经成为除石油天然气和消费品零售行业外,中国对外 相关公司股票走势 投资并购最活跃的三大行业之一。商务部公开信息显示,2014年中国实际对外投资总额约为1400亿美元,其中,生物医药约占整个市场份额的12%左右。  据中国 国际贸易 促进委员会公布的信息,从2009年到2013年,中国企业境外直接投资总额以年均17.5%的速度增长,并在2013年首次超过1000亿美元。从上海本地企业的交易数量及金额看,健康医疗及服务都占了约5-10%的份额。  目前全球生物医药市场呈高度集中态势。L.E.K(艾意凯)咨询的报告称,至2016年,北美、欧盟主要国家以及日韩的医药市场支出,将近全球总支出的60%。但发展中国家的市场增长更快,金砖四国的五年期市场年复合增长率(至2016年)超过10%,而同期美国的年复合增长率为3%左右,欧盟五国(德、法、意、英、西)的平均年复合增长率则为1%左右。  L.E.K(艾意凯)咨询认为,美国医疗市场的投资重点为:门槛更低的非处方药、保健营养品、各类医疗设备和器械,以及与研发戚戚相关的实验室和影像设备。在美国和其他发达市场,生物医药公司会持续关注可穿戴诊断设备、孤儿药和生物类似药。医疗科技是大部分私募股权公司在医疗领域的投资重点。  印度市场的投资重点主要包括:专科医院及专科日托服务中心、诊断及病理学实验室、生物 医药制造 、定制化研究及生产服务。具体来看,印度的制药行业,尤其是仿制药,仍然是最受投资者青睐的市场。而印度的医疗服务供应商,比如医疗物流,近年来发展势头迅猛,也受到投资者追捧。  三因素助力并购重组  重组并购是我国医药产业集中度提升和做大做强的最佳选择。据统计,我国药厂数量为4516家,为美国药厂数的五倍,而中国药品市场规模仅为美国市场的1 3。中国药厂拥有的批文也均以仿制药3类和6类批文为主。这都充分显示我国医药企业低水平同质化竞争明显。  中国医药 企业要做大做强,亟须提高行业集中度来减少和避免低水平同质化竞争。毫无疑问,医药企业重组并购是减少同质化企业竞争的最直接和最便捷的方法。这也是未来 医药行业 提高行业集中度的最佳选择。  重组并购是集团企业壮大的内在需求。集团企业的重组并购,一方面可充分发挥企业规模效应,大幅提升收入和降低成本;另一方面,可促进内部资源优势互补,提升集团内部研发和营销能力。  强制性标准和认证也促进了行业内的重组并购。现阶段,国内众多中小医药企业均未通过新版GMP(2011年颁布,3年过渡期)、美国FDA和欧洲COS等强制认证标准,仍在非规范生长状态。盈利情况不佳的中小医药企业无力进行工艺和车间改造,以适应此类强制性标准和认证的要求,这为行业内大型医药企业并购中小企业提供了绝佳的机会。来源中国证券报)相关的主题文章: